Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche

Annals of the New York Academy of Sciences

Volumn 1335, Issue 1, 2015, Pages 10-22

  Quarona, Valeria ^a   Ferri, Valentina ^b   Chillemi, Antonella ^a   Bolzoni, Marina ^b   Mancini, Cristina ^f   Zaccarello, Gianluca ^a   Roato, Ilaria ^a   Morandi, Fabio ^d   Marimpietri, Danilo ^d   Faccani, Giuliano ^e   Martella, Eugenia ^f   Pistoia, Vito ^d   Giuliani, Nicola ^b   Horenstein, Alberto L ^a   Malavasi, Fabio ^a,c  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^d G GASLINI INSTITUTE   (Italy)

^e CTO HOSPITAL   (Italy)

^f UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Adenosine; CD38; Ectoenzymes; Mesenchymal stem cells; MSC; Osteoblasts; Osteoclasts

Indexed keywords

ADENOSINE; CD38 ANTIGEN; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1; INORGANIC PYROPHOSPHATASE; PHOSPHODIESTERASE;

ANIMAL; BONE MARROW; CELL SURVIVAL; ENZYMOLOGY; EXTRACELLULAR FLUID; HUMAN; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; PHYSIOLOGY;

ADENOSINE; ANIMALS; ANTIGENS, CD38; BONE MARROW; CELL SURVIVAL; EXTRACELLULAR FLUID; HUMANS; MULTIPLE MYELOMA; PHOSPHORIC DIESTER HYDROLASES; PYROPHOSPHATASES;

EID: 84920501414     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12485     Document Type: Article

References (70)

1. Goding, J.W. & M.C. Howard . 1998. Ecto-enzymes of lymphoid cells. Immunol. Rev. 161: 5-10.
2. Jin, D. et al. 2007. CD38 is critical for social behaviour by regulating oxytocin secretion. Nature 446: 41-45.
3. Malavasi, F. et al. 2011. CD38 and chronic lymphocytic leukemia: a decade later. Blood 118: 3470-3478.
4. Malavasi, F. et al. 2006. CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity. Mol. Med. 12: 334-341.
5. Hendriks, R.W., S. Yuvaraj & L.P. Kil . 2014. Targeting Bruton's tyrosine kinase in B cell malignancies. Nat. Rev. Cancer 14: 219-232.
6. Quarona, V. et al. 2013. CD38 and CD157: a long journey from activation markers to multifunctional molecules. Cytometry B Clin. Cytom. 84: 207-217.
7. Yin, T. & L. Li . 2006. The stem cell niches in bone. J. Clin. Invest. 116: 1195-1201.
8. Cecati, M. et al. 2013. Contribution of adenosine-producing ectoenzymes to the mechanisms underlying the mitigation of maternal-fetal conflicts. J. Biol. Regul. Homeost. Agents 27: 519-529.
9. Malavasi, F. et al. 2008. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol. Rev. 88: 841-886.
10. Aarhus, R. et al. 1995. ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP. J. Biol. Chem. 270: 30327-30333.
11. Horenstein, A.L. et al. 2013. A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology 2: e26246.
12. Chillemi, A. et al. 2014. CD38 and bone marrow microenvironment. Front Biosci. (Landmark Ed). 19: 152-162.
13. Takahashi, T., L.J. Old & E.A. Boyse . 1970. Surface alloantigens of plasma cells. J. Exp. Med. 131: 1325-1341.
14. Abney, E.R., W.H. Evans & R.M. Parkhouse . 1976. Location of nucleotide pyrophosphatase and alkaline phosphodiesterase activities on the lymphocyte surface membrane. Biochem. J. 159: 293-299.
15. Buckley, M.F. et al. 1990. Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, amino acid sequence, and chromosomal location. J. Biol. Chem. 265: 17506-17511.
16. Kato, K. et al. 2012. Crystal structure of Enpp1, an extracellular glycoprotein involved in bone mineralization and insulin signaling. Proc. Natl. Acad. Sci. U. S. A. 109: 16876-16881.
17. Goding, J.W. 2000. Ecto-enzymes: physiology meets pathology. J. Leukoc. Biol. 67: 285-311.
18. Goding, J.W., B. Grobben & H. Slegers . 2003. Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family. Biochim. Biophys. Acta 1638: 1-19.
19. Junger, W.G. 2011. Immune cell regulation by autocrine purinergic signalling. Nat. Rev. Immunol. 11: 201-212.
20. Antonioli, L. et al. 2013. CD39 and CD73 in immunity and inflammation. Trends Mol. Med. 19: 355-367.
21. Heine, P. et al. 2001. The C-terminal cysteine-rich region dictates specific catalytic properties in chimeras of the ectonucleotidases NTPDase1 and NTPDase2. Eur. J. Biochem. 268: 364-373.
22. Mascanfroni, I.D. et al. 2013. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat. Immunol. 14: 1054-1063.
23. Dwyer, K.M. et al. 2007. CD39 and control of cellular immune responses. Purinergic Signal. 3: 171-180.
24. Saze, Z. et al. 2013. Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood 122: 9-18.
25. Eltzschig, H.K. et al. 2009. Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 113: 224-232.
26. Chalmin, F. et al. 2012. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 36: 362-373.
27. Bastid, J. et al. 2013. ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 32: 1743-1751.
28. Yegutkin, G.G. et al. 2012. Metabolism of circulating ADP in the bloodstream is mediated via integrated actions of soluble adenylate kinase-1 and NTPDase1/CD39 activities. FASEB J. 26: 3875-3883.
29. Heuts, D.P. et al. 2012. Crystal structure of a soluble form of human CD73 with ecto-5′-nucleotidase activity. Chembiochem 13: 2384-2391.
30. Coffey, F. et al. 2014. The TCR ligand-inducible expression of CD73 marks gammadelta lineage commitment and a metastable intermediate in effector specification. J. Exp. Med. 211: 329-343.
31. Thompson, L.F. et al. 2004. Crucial role for ecto-5′-nucleotidase (CD73) in vascular leakage during hypoxia. J. Exp. Med. 200: 1395-1405.
32. Stagg, J. 2012. The double-edge sword effect of anti-CD73 cancer therapy. Oncoimmunology 1: 217-218.
33. Zhang, B. 2012. CD73 promotes tumor growth and metastasis. Oncoimmunology 1: 67-70.
34. Terp, M.G. et al. 2013. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells. J. Immunol. 191: 4165-4173.
35. Antonioli, L. et al. 2013. Immunity, inflammation and cancer: a leading role for adenosine. Nat. Rev. Cancer 13: 842-857.
36. Waldron, T.J. et al. 2013. Myeloid derived suppressor cells: Targets for therapy. Oncoimmunology 2: e24117.
37. Deussen, A., M. Borst & J. Schrader . 1988. Formation of S-adenosylhomocysteine in the heart. I: An index of free intracellular adenosine. Circ. Res. 63: 240-249.
38. Fredholm, B.B. et al. 2011. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol. Rev. 63: 1-34.
39. Baldwin, J.M. 1994. Structure and function of receptors coupled to G proteins. Curr. Opin. Cell Biol. 6: 180-190.
40. Schoneberg, T., A. Schulz & T. Gudermann . 2002. The structural basis of G-protein-coupled receptor function and dysfunction in human diseases. Rev. Physiol. Biochem. Pharmacol. 144: 143-227.
41. Sheth, S. et al. 2014. Adenosine receptors: expression, function and regulation. Int. J. Mol. Sci. 15: 2024-2052.
42. Takedachi, M. et al. 2012. CD73-generated adenosine promotes osteoblast differentiation. J. Cell Physiol. 227: 2622-2631.
43. Vallario, A. et al. 1999. Human myeloma cells express the CD38 ligand CD31. Br. J. Haematol. 105: 441-444.
44. Uccelli, A., L. Moretta & V. Pistoia . 2008. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8: 726-736.
45. Nam, H.K. et al. 2011. Ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) protein regulates osteoblast differentiation. J. Biol. Chem. 286: 39059-39071.
46. Eltzschig, H.K., M.V. Sitkovsky & S.C. Robson . 2012. Purinergic signaling during inflammation. N. Engl. J. Med. 367: 2322-2333.
47. Grenz, A. et al. 2012. Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J. Clin. Invest. 122: 693-710.
48. Pastor-Anglada, M. et al. 2007. Concentrative nucleoside transporters (CNTs) in epithelia: from absorption to cell signaling. J. Physiol. Biochem. 63: 97-110.
49. Takahashi, H.K. et al. 2007. Effect of adenosine receptor subtypes stimulation on mixed lymphocyte reaction. Eur. J. Pharmacol. 564: 204-210.
50. Hasko, G. et al. 2008. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 7: 759-770.
51. Lau, W.M. et al. 2013. Enpp1: a potential facilitator of breast cancer bone metastasis. PLoS One 8: e66752.
52. Saborit-Villarroya, I. et al. 2011. E2A is a transcriptional regulator of CD38 expression in chronic lymphocytic leukemia. Leukemia 25: 479-488.
53. Long, C.L. et al. 2012. E proteins regulate osteoclast maturation and survival. J. Bone Miner. Res. 27: 2476-2489.
54. Zumaquero, E. et al. 2010. Exosomes from human lymphoblastoid B cells express enzymatically active CD38 that is associated with signaling complexes containing CD81, Hsc-70 and Lyn. Exp. Cell Res. 316: 2692-2706.
55. Gorgun, G.T. et al. 2013. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 121: 2975-2987.
56. Favaloro, J. et al. 2014. Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leuk. Lymphoma [Epub ahead of print, May 12].
57. + myeloid-derived suppressor cells. PLoS One 7: e48871.
58. Guichelaar, T. et al. 2013. Human regulatory T cells do not suppress the antitumor immunity in the bone marrow: a role for bone marrow stromal cells in neutralizing regulatory T cells. Clin. Cancer Res. 19: 1467-1475.
59. Ebstein, R.P. et al. 2011. Are retinoids potential therapeutic agents in disorders of social cognition including autism? FEBS Lett. 585: 1529-1536.
60. Colaianni, G. et al. 2012. Bone marrow oxytocin mediates the anabolic action of estrogen on the skeleton. J. Biol. Chem. 287: 29159-29167.
61. Colaianni, G. et al. 2011. Regulated production of the pituitary hormone oxytocin from murine and human osteoblasts. Biochem. Biophys. Res. Commun. 411: 512-515.
62. Colaianni, G. et al. 2014. The oxytocin-bone axis. J. Neuroendocrinol. 26: 53-57.
63. Higashida, H. et al. 2011. CD38 gene knockout juvenile mice: a model of oxytocin signal defects in autism. Biol. Pharm. Bull. 34: 1369-1372.
64. Lopatina, O. et al. 2014. Anxiety- and depression-like behavior in mice lacking the CD157/BST1 gene, a risk factor for Parkinson's disease. Front Behav. Neurosci. 8: 133.
65. Burnstock, G. 2014. Purinergic signalling in endocrine organs. Purinergic Signal. 10: 189-231.
66. Lux, A. et al. 2014. A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity. Cell Rep. 7: 236-248.
67. Laubach, J.P. et al. 2014. Daratumumab granted breakthrough drug status. Expert Opin. Invest. Drugs 23: 445-452.
68. Chillemi, A. et al. 2013. Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule. Mol. Med. 19: 99-108.
69. Quarona and Malavasi et al. 2014. In preparation.
70. Mediero, A. & B.N. Cronstein . 2013. Adenosine and bone metabolism. Trends Endocrinol. Metab. 24: 290-300.